Bortezomib

Potent and selective proteasome inhibitor (Ki=0.6 nM) [1]. Inhibits proliferation of a number of tumor cell lines (IC50=7 nM) [2]. Inhibits TNFα synthesis and FGF-induced angiogenesis. Clinically useful agent for treatment of multiple myeloma [3]. Shows promise in the treatment of neurodegenerative diseases in which low-expressing proteins such as IKAP/hELP1 in familial dysautonomia are preserved [4]. Reversible. Cell permeable.

References:

1) J Adams et al. Cancer Res. 1999 59:2615

2) S Williams et al. Mol. Cancer Ther.  2003 2:835

3) PG Richardson et al. Cancer Control.  2003 10:361

4) M Herve and EC Ibrahim Neurobiol. Dis.  2017 103:113